









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on March 2024

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
DoubleBase ONCE gel			X	HUTH- Deferred as meeting with dermatology to discuss
Slynd (drospirenone)	AMB 2			CHCP
3) New formulations & extensions to use				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Nil this month				
4) Products considered by NICE				
TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA947: Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA948: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
HST30: Sebelipase alfa for treating Wolman disease	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner. Neither HUTH nor NLAG are specialist centres – to reflect NHS England SSCs.
5) Appeals against earlier decisions by the APC				
Nil this month				
6) Miscellaneous formulary decisions by the APC				
Anastrozole	AMB 1			For primary prevention familial of breast cancer
Lursidone	AMB 2			

The following guidelines were presented to and approved at the March 2024 meeting of the APC:

- Orthostatic Hypotension
- Corticosteroid inhaler

DECISION SUMMARY

The following Drug information leaflets were presented to and approved at the March 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the March 2024 meeting of the APC:

- ADHD SCF NEL updates

Other documents presented to and approved at the March 2024 meeting of the APC:

- Nil this month